Abstract
This paper offers a framework for managing a comprehensive Global Access Strategy for new vaccines in developing countries. It is aimed at strengthening the ability of public-sector entities to reach their goals. The Bill and Melinda Gates Foundation and The Rockefeller Foundation have been leaders in stimulating the creation of new organizations - public/private product development partnerships (PDPs) - that seek to accelerate vaccine development and distribution to meet the health needs of the world's poor. Case studies of two of these PDPs - the Salmonella Anti-pneumococcal Vaccine Program and the Pediatric Dengue Vaccine Initiative - examine development of such strategies. Relying on the application of innovation theory, the strategy leads to the identification of six Components of Innovation which cover all aspects of the vaccine innovation process. Appropriately modified, the proposed framework can be applied to the development and introduction of other products in developing countries including drugs, and nutritional and agricultural products.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4003-4011 |
| Number of pages | 9 |
| Journal | Vaccine |
| Volume | 25 |
| Issue number | 20 |
| DOIs | |
| State | Published - May 16 2007 |
Fingerprint
Keywords
- Access
- Developing country
- Innovation
- Vaccine
ASJC Scopus subject areas
- Immunology
- Microbiology
- Virology
- Infectious Diseases
- Public Health, Environmental and Occupational Health
- veterinary(all)
Cite this
The introduction of new vaccines into developing countries. IV : Global Access Strategies. / Mahoney, Richard T.; Krattiger, Anatole; Clemens, John D.; Curtiss, Roy.
In: Vaccine, Vol. 25, No. 20, 16.05.2007, p. 4003-4011.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The introduction of new vaccines into developing countries. IV
T2 - Global Access Strategies
AU - Mahoney, Richard T.
AU - Krattiger, Anatole
AU - Clemens, John D.
AU - Curtiss, Roy
PY - 2007/5/16
Y1 - 2007/5/16
N2 - This paper offers a framework for managing a comprehensive Global Access Strategy for new vaccines in developing countries. It is aimed at strengthening the ability of public-sector entities to reach their goals. The Bill and Melinda Gates Foundation and The Rockefeller Foundation have been leaders in stimulating the creation of new organizations - public/private product development partnerships (PDPs) - that seek to accelerate vaccine development and distribution to meet the health needs of the world's poor. Case studies of two of these PDPs - the Salmonella Anti-pneumococcal Vaccine Program and the Pediatric Dengue Vaccine Initiative - examine development of such strategies. Relying on the application of innovation theory, the strategy leads to the identification of six Components of Innovation which cover all aspects of the vaccine innovation process. Appropriately modified, the proposed framework can be applied to the development and introduction of other products in developing countries including drugs, and nutritional and agricultural products.
AB - This paper offers a framework for managing a comprehensive Global Access Strategy for new vaccines in developing countries. It is aimed at strengthening the ability of public-sector entities to reach their goals. The Bill and Melinda Gates Foundation and The Rockefeller Foundation have been leaders in stimulating the creation of new organizations - public/private product development partnerships (PDPs) - that seek to accelerate vaccine development and distribution to meet the health needs of the world's poor. Case studies of two of these PDPs - the Salmonella Anti-pneumococcal Vaccine Program and the Pediatric Dengue Vaccine Initiative - examine development of such strategies. Relying on the application of innovation theory, the strategy leads to the identification of six Components of Innovation which cover all aspects of the vaccine innovation process. Appropriately modified, the proposed framework can be applied to the development and introduction of other products in developing countries including drugs, and nutritional and agricultural products.
KW - Access
KW - Developing country
KW - Innovation
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=34247208505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247208505&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2007.02.047
DO - 10.1016/j.vaccine.2007.02.047
M3 - Article
VL - 25
SP - 4003
EP - 4011
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 20
ER -